Dr. Dayle Hogg joined GammaDelta Therapeutics in 2017 from Kesios Therapeutics, where he was Chief Operating Officer. Previously, Dayle was Investment Manager at Touchstone Innovations (formerly Imperial Innovations), where he was part of the team focusing on investments in therapeutics and medical device businesses. Dayle has previously led or participated in a number of Seed and Series A investments for therapeutics businesses on behalf of Touchstone Innovations. Prior to joining Touchtone Innovations, Dayle worked in commercial roles within the biotechnology sector, and has more than 15 years’ operational experience of drug discovery and development across multiple therapeutic fields. As former Commercial Vice President of Lectus Therapeutics, he was responsible for the closure of a number of licensing and divestment transactions, including a licensing and acquisition transaction with UCB.
Dayle has a DPhil in Pharmacology from the University of Oxford and a degree in Pharmacology from the University of Leeds. He is also a current non-executive director of Lymphact – Lymphocyte Activation Technologies, S.A. (a subsidiary of GammaDelta Therapeutics) and Kesios Therapeutics.